West Pharmaceutical Services, Inc. (WST)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,147 | 2,831 | 2,886 | 2,951 | 2,893 | 3,074 | 3,327 | 3,374 |
| Operating profit | $m | 617 | 687 | ||||||
| Net profit | $m | 346 | 662 | 586 | 593 | 493 | 494 | 565 | 651 |
| EPS reported | $ | 6.80 | 7.82 | ||||||
| Operating cashflow per share | $ | 10.44 | 9.35 | ||||||
| Capex per share | $ | 3.95 | 3.18 | ||||||
| FCF per share | $ | 6.49 | 6.17 | ||||||
| Free cash flow | $m | 469 | 437 | ||||||
| Net debt | $m | -470 | -233 | ||||||
| Book value equity | $m | 3,176 | 2,990 | ||||||
| Book value per share | $ | 43.69 | 41.94 | ||||||
| Number of shares | m | 72.7 | 71.3 | ||||||
| DPS (TTM paid) | $ | 0.85 | 0.88 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 40.46 | 47.37 | ||||||
| P/B LTM | x | 6.26 | 6.65 | ||||||
| P/S LTM | x | 6.47 | 5.98 | ||||||
| P/FCF LTM | x | 42.42 | 45.53 | ||||||
| EV/EBITDA LTM | x | 26.97 | 23.68 | ||||||
| EV/Sales LTM | x | 6.35 | 7.48 | ||||||
| Earnings Yield LTM | % | +2.47% | +2.11% | ||||||
| FCF Yield | % | +2.36% | +2.20% | ||||||
| Quality | |||||||||
| ROE | % | +15.54% | +18.51% | ||||||
| ROIC | % | +13.62% | +15.77% | ||||||
| Operating margin | % | +20.09% | +20.64% | ||||||
| Gross margin | % | +35.89% | +36.77% | ||||||
| FCF/Sales | % | +15.26% | +13.13% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +1.64% | +16.89% | ||||||
| Sales Growth YoY | % | +6.26% | +15.00% | ||||||
| Net Income Growth YoY | % | +0.20% | +14.65% | ||||||
| FCF Growth | % | +69.65% | +58.07% | ||||||
| Operating Profit Growth | % | +3.83% | +15.46% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.31% | +0.25% | ||||||
| Dividend Growth | % | +4.94% | +8.64% | ||||||
| Payout Ratio | % | +12.38% | +11.04% | ||||||
| FCF/Debt | x | 1.13 | 1.40 | ||||||
| Net Debt/EBITDA | x | -0.52 | -0.15 | ||||||
| EBIT/Net interest | x | 1,029.00 | 6,865.00 | ||||||
| Net debt/market cap | % | +1.61% | +1.25% | ||||||
| Net debt/Equity | x | -0.15 | -0.08 | ||||||
| Gross debt/equity | x | 0.13 | 0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
West Pharmaceutical Services, Inc. (WST)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free